A drug carrier includes a structure represented by formula (1) defined as in the specification is provided. The drug carrier can be used as a drug delivery system. The drug delivery system can include the drug carrier and an effective amount of a nucleic acid, in which the nucleic acid is encapsulated in the drug carrier. The drug delivery system also can include the drug carrier and an effective amount of an active substance, in which the active substance is encapsulated in the drug carrier.

A light source emits light into a first portion of a living body. Functionalized particles within the body are configured to specifically bind to a target analyte, and upon receiving the emitted light, undergo a reaction that separates a detectable label from the functionalized particle. A sensor device is configured to detect a response signal from a second portion of the living body that is indicative of an abundance of the detectable label in the second portion. A control system uses the sensor device to obtain sensor data indicative of the response signal from the second portion of the living body detected by the sensor device during a measurement interval, and determines a presence or absence of the target analyte within the first portion of the living body based in part on the obtained data.

The invention provides a novel class of materials that possess triplet-triplet annihilation upconversion, compositions and methods of preparation and use thereof. The invention also relates to use of such materials and nanoparticles, for example, in stimulus-responsive, in situ delivery of biologically active agents.

A light-activated construct composed of two photoreceptive polypeptide domains connected to one another by a flexible linker is provided, as is a fusion protein containing the same and polynucleotides encoding said construct and fusion protein. Methods of making and using the light-activated construct and fusion protein are also provided.

A nanosample capable of near-infrared light-triggered release of therapeutic molecules. The nanosample includes a plurality of nanocomplexes. Each of the nanocomplexes includes a nanoshell; a host molecule linked to the nanoshell; and a guest molecule linked to the host molecule. The nanoshell includes a shell. The nanocomplex has a plasmon resonance wavelength. When irradiated with electromagnetic radiation of the plasmon resonance wavelength, plasmon resonance of the nanocomplex releases the guest molecule. The nanoshell may also include a core, where the shell surrounds the core. The nanoshell may be a nanomatryoshka. A link between the nanoshell and the host molecule may be a gold-thiol interaction. The shell may include at least one metal, such as gold or silver. The core may be a liposome and/or silica. The host molecule may be: synthetic polymers, biopolymers, polynucleotides, nucleic acids, polypeptides, polysaccharides, polyterpenes, lipids, aptamers, and/or proteins. The guest molecule may be: pharmaceutical molecules, biopharmaceutical molecules, oligonucleotides, nucleic acids, dye molecules, and/or imaging contrast agents. The host molecule may be: aptamer, single-stranded DNA, double-stranded DNA, and/or human serum albumin. The guest molecule may be: docetaxel, lapatinib, and/or tumor necrosis factor alpha. The plasmon resonance wavelength may be in a near-infrared (NIR) water window.

The present invention relates to an optical fiber and a device including the optical fiber. The optical fiber is an optical fiber (1) functionalized with at least one particle (1) of a polymeric gel comprising at least one photosensitive molecule (7) and at least one biomolecule (6), wherein the at least one particle (2) of the polymeric gel is covalently bound to said optical fiber (1).

The present invention is directed to a composition suitable for forming an implanted light activated drug depot, methods of making the composition, and methods and systems for using the composition. The composition comprises a plurality of drug conjugates, which comprise a drug molecule and a small solubility modulating portion. The drug conjugates are insoluble upon implantation as a drug depot into a subject, and the drug is preferably soluble once cleaved from the depot. One aspect of the invention is directed to a drug conjugate having a modulating portion that modifies the solubility of the drug conjugate by employing a hydrophobic non-polar moiety. Another aspect of the invention is directed to a drug conjugate having a modulating portion that modifies the solubility of the drug by employing a charged moiety that shifts the isoelectric point of the drug conjugate to a physiological pH.

The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.

The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.

A sensor that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing and an analyte indicator covering at least a portion of the sensor housing. The sensor may include a drug-eluting matrix that covers at least a portion of the analyte indicator. The drug-eluting matrix may include one or more openings configured to allow the medium to pass through the drug-eluting matrix and come into contact with the analyte indicator. The sensor may include one or more therapeutic agents. The one or more therapeutic agents may reduce deterioration of the analyte indicator. The one or more therapeutic agents may be incorporated within the drug-eluting matrix.